secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-06-25T20:02:15+00:00
Accession:  0001664710-26-000036
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros appoints Anne Prener to Board of Directors, effective July 1, 2026
------------------------------------------------------------------------

- Anne Prener, M.D., Ph.D., appointed as Class III director with term expiring at 2029 annual meeting.
- Initial equity grants: $150K option and $150K RSU, each vesting quarterly over three years.
- Annual compensation: $75K option, $75K RSU, and $41,500 cash retainer for board service.
- Dr. Prener brings clinical development leadership; formerly CEO of Imbria, Freeline, Gyroscope, and exec at Baxalta and Novo Nordisk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000036/0001664710-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000036/kros-20260623.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer